Tania Monzon

Tania Monzon

Auto-generated profile, based on publicly available information

Tania Monzon

Department of Hemodialysis, Avericum S.L., Las Palmas de Gran Canaria, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Clinical Kidney Journal
Verified
Journal Article
Open access
FVFrancisco Valga
Francisco Valga
NDNicanor Vega- Díaz
Nicanor Vega- Díaz
MMManuel Macia
Manuel Macia
TMTania Monzón
Tania Monzón
JRJosé Carlos Rodríguez-Pérez
José Carlos Rodríguez-Pérez

12 March 2021 in Case Reports in Nephrology
Verified
Journal Article
Open access
PDF file
JFJosé Carlos De La Flor
José Carlos De La Flor
FVFrancisco Valga
Francisco Valga
AMAlexander Marschall
Alexander Marschall
TMTania Monzon
Tania Monzon
CACristina Albarracín
Cristina Albarracín
MRMiguel Rodeles
Miguel Rodeles
Early reports have suggested that maintenance hemodialysis (MHD) patients could be more susceptible to a severe course of COVID-19. Among the therapeutic approaches, the use of drugs that reduce the cytokine storm characteristic of this disease has been proposed. Some dialyzers, such as the new generation of asymmetric cellulose triacetate (ATA) membranes, could favor the effective elimination of medium-sized molecules and other inflammatory mediators. In this case series, we describe in depth the clinical, analytical, and radiological details, therapeutic aspects, and outcomes of the case series of 10 MHD patients of our dialysis unit, who tested positive for SARS-CoV-2 from 5 October to 30 November 2020. Furthermore, we evaluate the removal of hyperinflammatory parameters with the ATA membrane in postdilution online hemodiafiltration (OL-HDF) in these patients through a variety of biomarkers of systemic inflammation from the diagnosis until stripping. Biochemical blood analysis was carried out at baseline and at days 7 and 14 after diagnosis, respectively. 50 of the patients presented COVID-19 pneumonia and required hospital admission. Median hospitalization time was 21days. A total of 4 patients developed severe pneumonia (3 of them died) and 1 patient developed moderate pneumonia. Patients who died (n=3) were more likely to present bilateral pneumonia (100 vs 14.3) at diagnosis and less reduction in interleukin 6 (IL-6) at day 14, as compared to those who survived. The use of the ATA membrane could be considered a therapeutic option, due to its immunomodulatory effect in MHD patients with SARS-CoV-2 infection, especially at the beginning of the disease, where the inflammatory component is predominant.

1 July 2020 in Nefrología (English Edition)
Verified
Journal Article
Open access
FVFrancisco Valga
Francisco Valga
NVNicanor Vega-Diaz
Nicanor Vega-Diaz
TMTania Monzon
Tania Monzon
FGFayna Gonzalez-Cabrera
Fayna Gonzalez-Cabrera
ASAdonay Santana
Adonay Santana
JRJosé Carlos Rodríguez-Pérez
José Carlos Rodríguez-Pérez